Caught Between Federal And State Laws, Pharmacists Seek Clarity On Providing Reproductive Services
American Society of Health-System Pharmacists wants HHS to clarify its guidance to pharmacies on their obligations in the wake of Supreme Court’s overturning of Roe v. Wade.
You may also be interested in...
What Might FDA Do Post Roe? Eliminate Mifepristone REMS
Attorneys say the biggest step FDA could take to expand access to medication abortion would be to eliminate REMS requirement for mifepristone. Timeline notes steps Biden administration and Congress have taken since the Supreme Court’s ruling overturning the right to an abortion.
US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade
HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.
Abortion Pill Mifepristone Will No Longer Require In-Person Pick Up, US FDA Concludes
REMS modification implemented for the duration of the pandemic will become permanent, the agency determines in response to lawsuit. FDA adds a requirement that pharmacies dispensing the drug be certified.